Advertisement
Home Day 3

Day 3

Economic Burden of Health Care Utilization for Paroxysmal Nocturnal Hemoglobinuria

Eculizumab is the current standard of care for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); however, some patients continue to experience ongoing...

Mental Health Screening Is Needed for Patients with Hematologic Cancers

A study presented at the 2020 ASH Annual Meeting found that about one-fifth of patients with hematologic cancers have depression and anxiety...

Dual Targeting CD19/CD22 CAR T-Cell Therapy Is Effective for ALL

A study presented at the 2020 ASH Annual Meeting assessed the safety of a dual-targeted CD19/CD22 chimeric antigen receptor (CAR) T-cell therapy...

Pegcetacoplan Versus Eculizumab for Change in Hemoglobin Level in Patients with Paroxysmal Nocturnal Hemoglobinuria

The phase III PEGASUS trial compared pegcetacoplan versus eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and found that pegcetacoplan induced...
Advertisement
Advertisement